Alterity Therapeutics Ltd (ath) Logo

Alterity Therapeutics Ltd (ATH)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

ATH Chart

ATH's Principal Activity is the commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +47.89%
vs ASX 200 (1yr) +10.50%

Size

Market Capitalisation
ASX Rank 1,166 of 2,237
Sector Rank 104 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies VLS / BPH / PTX
EPS -$0.011
DPS $0.00
NTA per share $1.69

Broker Consensus

ATH is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited) is an Australian biotechnology company which focusses to commercialise research into Parkinsonian movement disorders, Alzheimer's disease, Huntington disease and other neurodegenerative disorders.

Incorporation Details

Incorporated in VIC on 11/11/1997 as Prana Corporation Pty Ltd. Incorporation status changed to "Limited" on 26/11/1999. Name changed to Prana Biotechnology Limited on 05/01/2000.

Corporate Details

Head Office Melbourne VIC 3000
Website www.alteritytherapeutics.com
Registry Computershare
Auditor PricewaterhouseCoopers
Date Listed 28 Mar 2000

Upcoming Calendar

Date Event
30/08/2021 Report (Prelim)
08/09/2021 Report (Prelim)
08/09/2021 Report (Annual)
24/02/2022 Report (Interim)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr David Stamler Chief Executive Officer Jan 2021
Mr David Sinclair Non-Executive Director Apr 2019 Director Bio icon

Mr David Sinclair

Non-Executive Director

Dr Sinclair is the co-founder and chairman of Life Biosciences LLC. He is also a tenured professor in the Department of Genetics at Harvard Medical School, a co-director of the Paul F. Glenn Center for the Biology of Aging Research, and serves on the non-profit boards of the American Federation for Aging Research and the Sanford Lorraine Cross Award. He has co-founded biotechnology and genomics companies which work on aging, neurological, metabolic, infectious and rare diseases.

Mr Tristan Edwards Non-Executive Director Apr 2019 Director Bio icon

Mr Tristan Edwards

Non-Executive Director

Mr Edwards is the co-founder and President of Life Biosciences LLC. He has financial capital markets, regulatory compliance, and fiduciary oversight experience, following a 16 year investment career spanning financial organizations across Australia, London, HK and Singapore. His background has been in senior investment roles at financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital and Mosaic Asset Management. He started his career as an analyst with the Australian Commonwealth Department of Finance.

Mr Phillip Hains Company Secretary May 2014
Mr Lawrence Gozlan Non-Executive Director Aug 2011 Director Bio icon

Mr Lawrence Gozlan

Non-Executive Director

Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a investment fund which has focus in life sciences. Prior to this, Mr Gozlan was in charge for the biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"). He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr Gozlan is currently direcor of number of private biotechnology companies in the USA.

Mr Peter Ashley Marks Non-Executive Director Jul 2005 Director Bio icon

Mr Peter Ashley Marks

Non-Executive Director

Mr Marks for over 13 years until the end of August 2014 was a Director of Peregrine Corporate Ltd, an Australian-based investment banking and corporate advisory firm. Mr Marks was until 2016, a Director of Armadale Capital Plc, which has focus on natural resources projects based in Africa with its current investments being a gold exploration company in DRC and a coal briquetting operation in South Africa. Mr Marks is currently a Consultant at Henslow Pty Ltd, a corporate and capital markets advisory firm. Mr. Marks is also a nonexecutive director of Terragenic International Ltd, an unlisted public company and has develop a novel hydrogen fuel system. From September 1998 until March 2001, Mr Marks was working with KPMG Corporate Finance Ltd (Australia), where he rose to Director and was in charge for heading up the equity capital markets group in Melbourne. From January 1992 until July 1994, Mr. Marks served as Head of the Melbourne Companies Department at the ASX and was founding Director of Momentum Funds Management Pty Ltd, an Australian venture capital firm. From December 1990 until December 1991, Mr Marks served as Director of Corporate Finance at Burdett Buckeridge & Young Ltd in their Melbourne offices, from August 1988 until November 1990, he held senior corporate finance position at Barings Securities Ltd, and from July 1985 until July 1988, he served as an Associate Director of McIntosh Securities, now Merrill Lynch Australia. In his roles with these financial institutions, Mr Marks was in charge for advising a number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.

Mr Geoffrey Paul Kempler Non-Executive Chairman,Non-Executive Director Jun 2005 Director Bio icon

Mr Geoffrey Paul Kempler

Non-Executive Chairman,Non-Executive Director

Mr Kempler has served as our Chief Executive Officer, and in June 2005 he again assumed the position of Chief Executive Officer. Mr Kempler has experience in investment and business development, has been in charge for the implementation of our strategic plan and the commercialisation of our technology.

Mr Brian Derek Meltzer Non-Executive Director Dec 1999 Director Bio icon

Mr Brian Derek Meltzer

Non-Executive Director

Mr Meltzer spent 25 years in investment banking. His breadth of expertise includes property transactions, corporate advisory, corporate finance, management buyouts, venture capital and syndications. He has held a number of Board and Board Advisory roles for private companies in the human resources, health, aged care, software, entertainment and finance sectors, including Director of a federal government Innovation Investment Fund. Mr Meltzer is also a Director of the Australia-Israel Chamber of Commerce, Chairman of Independence Australia and Chairman of a privately owned corporate health and wellness business.

David Stamler Chief Executive Officer N/A
Kathryn Andrews Chief Financial Officer N/A

Director Transactions

ATH directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
18/09/20 Tristan Edwards Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Peter Marks Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Lawrence Gozlan Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Geoffrey Kempler Issued 14,000,000 $0.054 $756,000 Issue of options
18/09/20 David Sinclair Issued 7,000,000 $0.054 $378,000 Issue of options
18/09/20 Brian Meltzer Issued 7,000,000 $0.054 $378,000 Issue of options

Director Interests

The current holdings of ATH directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Tristan Edwards 18/09/2020 0 N/A 7,000,000 N/A
Lawrence Gozlan 18/09/2020 N/A N/A 8,250,000 N/A
Peter Marks 18/09/2020 43,111 N/A 8,250,000 N/A
Brian Meltzer 18/09/2020 326,666 N/A 8,250,000 N/A
Geoffrey Kempler 18/09/2020 30,000 17,981,000 19,000,000 N/A
David Sinclair 18/09/2020 0 N/A 7,000,000 N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Sep 7, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 523,867,497 48.28%
Life Biosciences Llc 269,905,533 24.88%
Baywick Proprietary Limited <The Retail Discretionary A/C> 14,165,000 1.31%
J P Morgan Nominees Australia Pty Limited 8,041,588 0.74%
Citos Super Pty Ltd <Citos Pty Ltd Sf A/C> 5,000,000 0.46%
Donatello Nizzi 4,678,362 0.43%
Mr James V Babcock 3,980,263 0.37%
Citicorp Nominees Pty Limited 3,705,746 0.34%
The Entrust Group Inc <Robert Davidow Ira A/C> 3,598,740 0.33%
Fagan Harris Pty Ltd <Fagan Harris Super Fund A/C> 3,249,715 0.30%
Mr Christopher Ferris 3,000,000 0.28%
NRB Developments Pty Ltd 2,970,000 0.27%
Capuano Nominees Pty Ltd <The Hartman Investment A/C> 2,750,000 0.25%
One Lucky Oak Pty Ltd <Oakshott Fam Super Fund A/C> 2,200,342 0.20%
Rentuk Shore Pty Ltd 2,128,205 0.20%
Mr Lukasz Pieprzyk 2,022,681 0.19%
Mr Mark Victor Gordon + Miss Linda June Grace Gordon <Mark Gordon R/F Account> 2,000,000 0.18%
Mr Shaun Anthony Neilsen 2,000,000 0.18%
Ms Pamela Joy Bates 2,000,000 0.18%
Moubray Pty Ltd <Robert Hallas Sf A/C> 2,000,000 0.18%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 510 1,401 822 1,883 438 5,054

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Life Biosciences LLC 24/11/2020 269,905,533 13.30
Regal Funds Management Pty Ltd 11/03/2021 136,945,316 6.57
The Bank of New York Mellon Corporation 18/02/2021 953,676,448 45.76

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
18-02-21 The Bank of New York Mellon Corporation 43,320,480 43.68 45.76
12-02-21 The Bank of New York Mellon Corporation 32,485,560 42.12 43.68
11-02-21 The Bank of New York Mellon Corporation 80,366,700 39.27 42.12
09-02-21 The Bank of New York Mellon Corporation 24,052,440 38.08 39.27
24-12-20 The Bank of New York Mellon Corporation 23,074,800 36.95 38.08
16-12-20 The Bank of New York Mellon Corporation 21,298,440 35.90 36.95
08-12-20 The Bank of New York Mellon Corporation 25,418,940 34.65 35.90
02-12-20 The Bank of New York Mellon Corporation 28,730,400 33.23 34.65
27-11-20 The Bank of New York Mellon Corporation 42,981,840 31.12 33.23
24-11-20 The Bank of New York Mellon Corporation 9,820,980 45.87 31.12
24-11-20 Regal Funds Management Pty Ltd 262,791,109 -- 12.94
23-11-20 The Bank of New York Mellon Corporation 26,350,440 43.93 45.87
20-11-20 The Bank of New York Mellon Corporation 40,946,340 40.91 43.93
19-11-20 The Bank of New York Mellon Corporation 21,587,460 39.32 40.91
17-11-20 The Bank of New York Mellon Corporation 14,688,900 38.23 39.32
11-11-20 Credit Suisse Holdings (Australia) Limited 68,047,174 -- 5.02
13-08-20 The Bank of New York Mellon Corporation 18,309,600 46.65 48.34
06-07-20 The Bank of New York Mellon Corporation 11,493,480 51.25 52.31
26-05-20 The Bank of New York Mellon Corporation 137,945,160 41.87 55.16
25-05-20 The Bank of New York Mellon Corporation 22,351,012 47.86 41.87

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
11-03-21 Regal Funds Management Pty Ltd 21,085,239 7.58 6.57
24-02-21 Regal Funds Management Pty Ltd 26,822,681 8.87 7.58
11-02-21 Regal Funds Management Pty Ltd 24,000,000 10.28 8.87
10-02-21 Regal Funds Management Pty Ltd 30,000,000 11.76 10.28
12-01-21 Regal Funds Management Pty Ltd 23,937,873 12.94 11.76
12-11-20 Credit Suisse Holdings (Australia) Limited 68,047,174 5.02 --
23-10-20 The Bank of New York Mellon Corporation 5,955,900 48.34 38.23
13-07-20 The Bank of New York Mellon Corporation 17,307,360 48.25 46.65
09-07-20 The Bank of New York Mellon Corporation 16,901,040 49.81 48.25
07-07-20 The Bank of New York Mellon Corporation 27,189,540 52.31 49.81
02-07-20 The Bank of New York Mellon Corporation 4,770,000 54.07 51.25
04-06-20 The Bank of New York Mellon Corporation 11,382,772 55.16 54.07

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.017 30 June
2019 $0.029 28 June
Page Icon
ATH Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.